Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Large Increase in Short Interest

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 4,015,500 shares, an increase of 6.9% from the November 30th total of 3,756,900 shares. Based on an average trading volume of 4,000 shares, the short-interest ratio is presently 1,003.9 days.

Innovent Biologics Trading Down 5.2 %

Shares of Innovent Biologics stock opened at $4.50 on Wednesday. The company has a 50-day moving average of $4.83 and a 200 day moving average of $5.18. Innovent Biologics has a 1 year low of $3.83 and a 1 year high of $6.40.

Innovent Biologics Company Profile

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.